The latest trading price for GNI Group Ltd., including after-hours PTS trading, is reported along with an overview of its interim earnings and developments such as the conversion of key subsidiaries into wholly owned subsidiaries. The stock was trading at around ¥2,870 in local after-hours trading.
GNI Group Ltd.'s trading data, including after-hours PTS trading, showed the stock fluctuating around ¥2,870 after hours, with only a small change from its closing price on the Tokyo Stock Exchange. The opening, high and low prices reported reflect trading during the after-hours session.
According to the earnings information, revenue for the interim period of the fiscal year ending December 2026 was approximately ¥11.9 billion, while operating profit turned positive at approximately ¥500 million. However, interim profit or loss attributable to owners of the parent was a loss of approximately ¥2.0 billion.
At the same time, while challenges remain in the medical device business, Ayumi Pharmaceutical Holdings is being made a wholly owned subsidiary and the integration of Cullgen is moving forward, which is expected to strengthen the business foundation.
Key points to watch in assessing future performance include steady sales of core drugs, progress in the F351 review, consideration of its introduction in Japan, and trends in integration costs.